A Phase 2, Single-Center, Open-Label Pilot Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection

Trial Profile

A Phase 2, Single-Center, Open-Label Pilot Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Oct 2017 Results of pooled analysis (n=294) describing the effectiveness of the single tablet regimen of ledipasvir/sofosbuvir using data from two prospective clinical trials (NCT02472886, NCT02480387) and four real world cohorts (German Hepatitis C-Registry,Madrid-CoRe,Veterans Health Administration,Saint Michaels), presented at the IDWeek 2017.
    • 22 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top